Dr. O'Donnell on PD-L1 Testing in Bladder Cancer

Video

In Partnership With:

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses PD-L1 testing in patients with bladder cancer.

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses PD-L1 testing in patients with bladder cancer.

PD-L1 testing is now required if a physician is considering using immunotherapy in the frontline setting for a cisplatin-ineligible patient with bladder cancer. It is also required if a physician plans on using immunotherapy in a patient who is chemotherapy-eligible, notes O’Donnell. However, if a patient is eligible to receive gemcitabine/carboplatin, O’Donnell tends to opt for that regimen over immunotherapy.

PD-L1 testing can also be used for patients who could receive either approach. If that type of patient is PD-L1—positive, O’Donnell recommends immunotherapy, whereas a patient who is PD-L1–negative might do better with gemcitabine/carboplatin, states O’Donnell.

Moreover, incorporating PD-L1 testing into practice is especially important following the FDA’s warning in May 2018 cautioning against the frontline use of single-agent immunotherapy, specifically pembrolizumab (Keytruda) or atezolizumab (Tecentriq), in PD-L1—low expressing platinum-eligible patients with advanced urothelial carcinoma.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,